Sanibel Captiva Trust Company Inc. Sells 6,016 Shares of Pfizer Inc. (NYSE:PFE)

Sanibel Captiva Trust Company Inc. cut its holdings in Pfizer Inc. (NYSE:PFE) by 7.2% during the 3rd quarter, Holdings Channel reports. The firm owned 77,189 shares of the biopharmaceutical company’s stock after selling 6,016 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in Pfizer were worth $2,234,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Olistico Wealth LLC bought a new stake in shares of Pfizer in the second quarter worth about $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer during the 2nd quarter valued at approximately $29,000. Quarry LP bought a new stake in Pfizer during the 2nd quarter valued at approximately $31,000. Creekmur Asset Management LLC bought a new stake in Pfizer during the 4th quarter valued at approximately $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its position in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $29.34 on Friday. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $33.92. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company’s fifty day simple moving average is $29.09 and its two-hundred day simple moving average is $28.36.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.73%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is -365.21%.

Analyst Ratings Changes

Several analysts have weighed in on PFE shares. Barclays lifted their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday. UBS Group lifted their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Thursday, October 3rd. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.